首页> 外文期刊>Human vaccines & immunotherapeutics. >The safety of influenza vaccine in clinically cured leprosy patients in China
【24h】

The safety of influenza vaccine in clinically cured leprosy patients in China

机译:流感疫苗在中国临床治愈麻风病患者中的安全性

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Leprosy is an infectious disease caused by the bacterium Mycobacterium leprae. Influenza vaccine is an important influenza prevention strategy and the preparations used display good safety and tolerability profiles. But the safety of applying influenza vaccine on the clinical cured leprosy patients is unclear.Methods: We conducted an observational clinical study, in Wuhan between November 15, 2016 and March 1, 2017. Two groups of participants 50years of age received a 0.5 ml dose of the inactivated split-virion trivalent influenza vaccine and a follow-up 28days observation of any solicited and unsolicited adverse events.Results: A total of 134 subjects were included in the study. The total rate of reactogenicity was 5.4% [2/37] in leprosy group and 15.5% [15/ 97] in control group, the difference of reactogenicity between two groups was not significant (p = 0.1522). For solicited injection-sites adverse events (AEs), 12.4% [12/ 97] participants in the control group reported of itching, pain, erythema, swelling or induration, and no participants in leprosy group reported of any solicited injection-sites AEs. For solicited systemic AEs, 7.2% [7 / 97] participants in the control group reported of fever, malaise or headache, and 2.7% [1 / 37] participants in the leprosy group reported of fever, statistic result showed that the difference was not significant (p = 0.4438). Unsolicited AEs was reported by one male aged 76, 4hours after vaccination administration, his plantar ulcer area began bleeding. All AEs were grade 1 or grade 2, and no recurrence of lepra reaction, AEs leading to early withdrawal from the study, or deaths were reported in this study.Conclusions: To our knowledge, the present study is the first clinical study to evaluate the safety of influenza vaccine in clinically cured leprosy patients. We concluded that clinically cured leprosy patients are relatively safe for influenza vaccine. More importantly, our study make a positive and scientific efforts to eradicatediscrimination on leprosy. In our study, we described a patient with plantar ulcer undergoing bleeding for 4hours after vaccine administration. Based on evidence we have, we interpret that this adverse event may probably associated with vaccine, and patients with ulcer and leprosy need intensive attention after vaccines administration.
机译:背景:麻风病是一种由细菌菌菌菌引起的传染病。流感疫苗是一个重要的流感预防策略,并且使用的制剂显示出良好的安全性和耐受性概况。但在临床治愈的麻风病患者上应用流感疫苗的安全性是不清楚的。方法:我们在2016年11月15日至2017年3月1日之间进行了一个观察临床研究,在武汉和2017年3月1日之间。两组参与者50年龄收到0.5毫升的剂量在灭活的分裂病毒血清患者的流感疫苗和后续28天观察任何征集和未经请求的不良事件。结果:研究中共有134名受试者。在麻黄基团中,反应发生的总速率为5.4%[2/37],对照组中15.5%[15/97],两组之间的反应性差异不显着(P = 0.1522)。对于征募注射部位的不良事件(AES),12.4%[12/97]对照组的参与者报告的瘙痒,疼痛,红斑,肿胀或硬结,并且在任何征集的注射座位AES报告的麻风病群中没有参与者。对于征集的全身AES,7.2%[7/97]对照组的参与者报告的发烧,萎靡不振或头痛,2.7%[1/37]参与者在发烧的麻风病群中,统计结果表明差异不是重要(p = 0.4438)。未经请求的AES由一个男性76岁的男性报告,疫苗接种给药后4小时,他的跖骨区域开始出血。所有AES都是1级或2级,并且没有雷帕反应的复发,导致早期戒断的AES或死亡在本研究中报告。结论:对我们的知识,本研究是评估的第一个临床研究流感疫苗在临床固化麻风病患者中的安全性。我们得出结论,临床治愈的麻风病患者对流感疫苗相对安全。更重要的是,我们的研究对麻风病症进行了积极和科学努力。在我们的研究中,我们描述了患有疫苗给药后4小时的植物溃疡的患者。根据我们的证据,我们解释了这种不良事件可能与疫苗有关,并且在疫苗给药后溃疡和麻风病患者需要强化注意。

著录项

  • 来源
  • 作者单位

    Wuhan Inst Dermatol &

    Venereol Dept Leprosy Wuhan Hubei Peoples R China;

    Jianghan Ctr Dis Prevent &

    Control Dept Immunizat Wuhan Hubei Peoples R China;

    Wuhan Inst Dermatol &

    Venereol Dept Leprosy Wuhan Hubei Peoples R China;

    Wuhan Ctr Dis Prevent &

    Control Dept Immunizat Wuhan Hubei Peoples R China;

    Wuhan Inst Dermatol &

    Venereol Dept Leprosy Wuhan Hubei Peoples R China;

    Wuhan Inst Dermatol &

    Venereol Dept Leprosy Wuhan Hubei Peoples R China;

    Wuhan Inst Dermatol &

    Venereol Dept Leprosy Wuhan Hubei Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    Leprosy; Influenza Vaccine; Safety; Ulcer; Reactogenicity;

    机译:麻风病;流感疫苗;安全;溃疡;反应源性;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号